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Abstract
Neuromyelitis optica (NMO) is a rare, disabling, sometimes fatal central nervous system inflammatory demyelinating disease that is
associated with antibodies (“NMO IgG”) that target the water channel protein aquaporin-4 (AQP4) expressed on astrocytes. There is
considerable interest in identifying environmental triggers that may elicit production of NMO IgG by AQP4-reactive B cells.
Although NMO is considered principally a humoral autoimmune disease, antibodies of NMO IgG are IgG1, a T-cell-dependent
immunoglobulin subclass, indicating that AQP4-reactive T cells have a pivotal role in NMO pathogenesis. When AQP4-specific
proliferative T cells were first identified in patients with NMO it was discovered that T cells recognizing the dominant AQP4 T-cell
epitope exhibited a T helper 17 (Th17) phenotype and displayed cross-reactivity to a homologous peptide sequence within a protein
of Clostridium perfringens, a commensal bacterium found in human gut flora. The initial analysis of gut microbiota in NMO
demonstrated that, in comparison to healthy controls (HC) and patients with multiple sclerosis, the microbiome of NMO is distinct.
Remarkably, C. perfringenswas the second most significantly enriched taxon in NMO, and among bacteria identified at the species
level, C. perfringenswas the one most highly associated with NMO. Those discoveries, along with evidence that certain Clostridia
in the gut can regulate the balance between regulatory T cells and Th17 cells, indicate that gut microbiota, and possibly
C. perfringens itself, could participate in NMO pathogenesis. Collectively, the evidence linking microbiota to humoral and cellular
immunity in NMO underscores the importance for further investigating this relationship.
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Introduction
Neuromyelitis optica (NMO) is a rare central nervous system
(CNS) autoimmune inflammatory demyelinating disease
characterized by attacks of transverse myelitis and optic neu-
ritis that may lead to severe, disabling paralysis and loss of
vision [1]. For many years, NMO was thought to be a severe
atypical form of multiple sclerosis (MS), a more common
CNS inflammatory demyelinating disease that is considered
to target oligodendrocyte-derived myelin proteins [2]. In con-
trast with MS, distinguished by disseminated white matter
lesions containing predominantly lymphocytes, NMO lesions
are restricted primarily to the spinal cord, brainstem and optic
nerves, and are characterized by the presence of neutrophils
and eosinophils, and deposition of antibody and complement
[3]. Understanding of the pathogenesis of NMO has advanced
rapidly since 2004, when it was discovered that NMO is as-
sociated with the serologic biomarker, NMO IgG [4]. Shortly
thereafter, aquaporin-4 (AQP4), a water channel protein
expressed abundantly on astrocyte end-foot membranes in
areas contacting the blood–brain barrier (BBB) [5], was iden-
tified as the primary target of NMO IgG [6]. The antibodies of
NMO IgG target conformational determinants exposed on ex-
tracellular loops of AQP4. Experimental evidence has con-
firmed that those AQP4-specific antibodies, together with
complement, can injure or destroy astrocytes [7]. NMO is
therefore considered primarily an autoimmune astrocytopathy.
Despite identification of AQP4 as the principal target, the
initial pathophysiologic events that lead to development of
NMO have remained elusive. Besides genetic factors that
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may predispose to NMO, investigators have considered pos-
sible environmental triggers, including plants, bacteria, or vi-
ruses that could elicit AQP4-specific antibodies [8–10].
“Molecular mimicry”, which can occur when a foreign protein
that shares structural or amino-acid sequence homologywith a
self-antigen elicits cross-reactive immunity [11], is implicated
in the pathogenesis of several rheumatologic and CNS auto-
immune disorders [12–15]. In this context, some researchers
have focused on the identification of foreign proteins that
share structural or amino-acid sequence homology with
AQP4 [9, 10]. One search of bacterial and viral proteins re-
vealed extensive homology between a Klebsiella pneumoniae
transmembrane protein and AQP4 but found no evidence for
cross-reactivity in NMO [16]. Other investigators suggested
that closely related bacterial aquaporins (e.g., aquaporin-Z
[17]) could elicit cross-reactivity and provided some experi-
mental evidence supporting their hypothesis. While much ef-
fort has been devoted to understanding the origin and patho-
physiologic role of NMO IgG, the potential role of Tcells, and
cellular immune response in general in AQP4 immunity has
received less attention. The AQP4-specific T cell may be the
cryptic immunologic linchpin in NMO, providing a link be-
tween microbiota and NMO pathogenesis.
Identification of AQP4-Specific T Cells
Suggests a Potential Role for Commensal
Gut Bacteria in NMO Pathogenesis
Several early observations suggested that T cells participate in
NMO pathogenesis. First, the AQP4-specific antibodies of
NMO IgG are IgG1, a T-cell-dependent immunoglobulin sub-
type. Some data suggest that T follicular helper cells, the
CD4+ T-cell subset that directs B-cell maturation, isotype
switching, and differentiation to Ig-secreting plasma cells
[18], are elevated in NMO [19, 20]. Second, epidemiologic
and genetic studies most frequently associate NMO occur-
rence with certain allelic major histocompatibility complex
(MHC) class II genes, which encode the transmembrane pro-
teins expressed on antigen presenting cells (APCs) that asso-
ciate with peptide fragments and are presented to antigen-
specific CD4+ T cells. In this regard, several NMO studies
have identified over-representation of patients carrying
HLA-DR1*0301 (DR17), DRB3*0202, and DPB1*0501
genes in different ethnic populations [21–23]. Furthermore,
HLA-DRB1*1501, the most common MS susceptibility al-
lele, is not associated with NMO [24]. Third, despite the pre-
dominance of neutrophils and eosinophils, T cells are also
detected in NMO lesions [3, 25], and elevated levels of inter-
leukin (IL)-17 and interferon-γ (proinflammatory T-cell-
derived cytokines) have been detected in the cerebrospinal
fluid of patients with NMO [26, 27]. Thus, besides directing
antibody production by AQP4-reactive B cells, T cells likely
contribute to the development of NMO lesions. In this respect,
in 2009 it was observed that neither recombinant AQP4-
specific antibodies [28] nor NMO IgG alone [29] were path-
ogenic in vivo. However, those AQP4-specific antibodies pro-
duced NMO-like lesions in rats that had received encephali-
togenic myelin-specific T cells, findings that are consistent
with the notion that cellular immune-mediated CNS inflam-
mation causing loss of integrity of the BBB may be a prereq-
uisite for CNS penetration of AQP4-specific antibodies.
Collectively, these observations inspired researchers to search
for AQP4-specific CD4+ T cells in NMO.
Working around the same time, investigators from Japan
[30], the USA [31], and Israel [32] identified AQP4-reactive T
cells in patients with NMO. All 3 groups observed that the
numbers of AQP4-reactive T cells were elevated in NMO in
comparison with HC. The 2 teams that studied T-cell re-
sponses to overlapping 20-mer peptides (p) spanning the
length of AQP4 identified multiple determinants, which in-
cluded an epitope within p61-80 [30, 31]. When our group
measured T-cell activation and proliferation, p61-80 was iden-
tified as the one AQP4 determinant recognized most frequent-
ly in patients with NMO [31] (see Fig. 1). CD4+ T cells from
patients with NMO that recognized this immunodominant
AQP4 T-cell determinant exhibited T helper (Th)17 polariza-
tion [31], an observation that added key support to the existing
clinical and histologic evidence indicating that Th17 cells
have a central role in NMO pathogenesis.
In general, CD4+ T cells recognize linear peptide frag-
ments of 12 to 14 amino acids that are produced during
protein degradation by APCs [33]. By examining the fine
specificity of T cells targeting the immunodominant AQP4
p61-80, its epitope was mapped to amino-acid residues 63 to
76. A search for homologous proteins revealed that this
epitope contained a 10-residue sequence (66–75) with 90%
homology to a sequence (207–216) within the adenosine
triphosphate binding cassette transporter permease (ABC-
TP) expressed by Clostridium perfringens, a ubiquitous an-
aerobic Gram-positive spore forming bacteria found in hu-
man commensal gut flora. Such a high level of homology is
nearly unprecedented. In comparison, studies of T-cell mo-
lecular mimicry in MS have identified and focused on T-cell
epitopes of myelin antigens that frequently share much less
homology with foreign antigens [34–36]. We observed that
Th17 cells from patients with NMO, which recognized the
immunodominant AQP4 epitope also proliferated in re-
sponse to the corresponding C. perfringens ABC-TP pep-
tide. Our serendipitous discovery suggesting a connection
between C. perfringens and AQP4-specific T-cell reactivity
in NMO could not be overlooked. Together with the emerg-
ing appreciation that gut microbiota can influence cellular
and humoral immunity, these observations provided a clear
foundation justifying the examination of gut microbiota in
NMO.
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Analysis of NMO Gut Microbiota Reveals
Dysbiosis and Overabundance of Clostridium
perfringens
Understanding the role of microbiota in human disease is in-
creasing at a tremendous pace [37, 38]. Newborns become
colonized with numerous microbes shortly after birth and,
while the number of organisms stabilizes after the first year,
microbial composition continues to vary in response to envi-
ronmental changes [39].Microbiota within the gastrointestinal
tract, comprising a community of 1013–14 organisms, are par-
ticularly heterogeneous [37]. Gram-negative Bacteroides and
Gram-positive Firmicutes, including Clostridiales and
Lactobacillales, are the major phyla represented in the gut of
healthy individuals. It has long been recognized that bacterial
species within commensal gastrointestinal flora participate co-
operatively in host functions. Specifically, gut microbiota gen-
erate metabolites de novo and also modify host-derived me-
tabolites, producing certain vitamins, fatty acids, amino acids,
and polyamines that are essential to immune regulation or
mucosal defense [40, 41]. More recently, shifts within
microbial communities have been associated with specific
diseases. Helicobacter pylori dominates gastric microbiota in
peptic ulcer disease, and over-representation of distinct spe-
cies of gastrointestinal bacteria have been identified in colo-
rectal cancer, type I diabetes mellitus, inflammatory bowel
disease, rheumatoid arthritis, Parkinson’s disease, and MS
[38, 42–46]. In 2008, it was observed that polysaccharide A
(PSA) produced by Bacteroides fragilis, which are found with-
in the terminal ileum, promoted expansion of IL-10-producing
regulatory T cells (Treg) [47, 48] and a later study showed that
PSA expression conferred resistance to experimental autoim-
mune encephalomyelitis (EAE) in mice [48]. At the time we
proposed studying the gut microbiome in NMO, it had been
shown that commensal anaerobic spore-forming (chloroform-
resistant) Clostridium within clusters IVand XIVa, abundant in
the colon of mice [49], and that Clostridia strains within clus-
ters IV, XIVa, and XVIII isolated from human fecal material
[50], also induced Tregs [49, 50]. In contrast, colonization of
the terminal ileumwith segmented filamentous bacteria, a com-
mensal anaerobic Gram-positive spore-forming bacteria closely
related to the genus Clostridium, was associated with
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Fig. 1 CD4+ T cells from patients
with neuromyelitis optica (NMO)
recognize discrete aquaporin-4
(AQP4) epitopes. (A) Peripheral
blood mononuclear cells (PBMC)
from patients with NMO and
healthy controls (HC) were
labeled with 5,6-
carboxyfluorescein diacetate
succinimidyl ester (CFSE) and
stimulated with AQP4 peptides.
Proliferation of CD4+ T cells was
measured by CFSE dilution. Cell
division index (CDI) > 2 (broken
lines) was considered positive.
(B) Recall T-cell proliferation to
individual AQP4 peptides was
detected by [3H]-thymidine
incorporation after initial
stimulation with recombinant
human AQP4. Adapted from
Varrin-Doyer, et al., Ann Neurol
72:53-64 (2012). Reproduced
with permission of John Wiley &
Sons [31]
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differentiation of proinflammatory Th17 cells [51] in mice and
increased susceptibility to EAE [52]. These findings were par-
ticularly intriguing, as differentiation of naive T cells into either
Th17 cells or Treg is controlled in a reciprocal manner [53].
Thus, it is plausible that a Clostridium species may alter the
balance between proinflammatory and anti-inflammatory T-cell
subsets in human disease.
Currently, the results from 1 NMO gut microbiome
study have been reported [54]. In that investigation, we
examined stool samples obtained from 16 patients with
AQP4-seropositive NMO, 16 patients with MS, and 16
HCs. Principal component analysis demonstrated compo-
sitional differences between those bacterial communities.
Whereas > 800 organizational taxonomic units were iden-
tified that differed in relative abundance between NMO
and HC, only 42 retained statistical significance follow-
ing correction for multiple comparisons (see Fig. 2). In
contrast, of nearly 300 organizational taxonomic units
that exhibited differential abundance between MS and
HCs, none withstood similar correction. Because a ma-
jority of the patients with NMO were treated with ritux-
imab or another immunosuppressive treatment, which
could hypothetically alter the gut microflora, patients
with MS treated with rituximab were included as added
controls. Differences in the gut microbiota between ritux-
imab-treated MS patients and rituximab-treated NMO pa-
tients were identified, indicating that dissimilarities be-
tween NMO and MS could not be attributed entirely to
that treatment (see Fig. 3). Thus, regardless of whether
the analysis included the entire dataset or individual sub-
sets, results indicated that there are distinct changes in
the NMO microbiota.
Remarkably, of bacteria identified at the species level,
C. perfringens was the species most significantly enriched
in patients with NMO compared with HCs (Table 1). Only
an unclassified species of Fibrobacteres had a more sig-
nificant p-value. In a 3-way analysis, C. perfringens was
overabundant in NMO versus either HC or MS. Although
C. perfringens was also over-represented in MS samples,
the significance was marginal and did not survive statis-
tical correction for multiple comparisons. Rituximab treat-
ment did not influence abundance of C. perfringens in
patients with either NMO or MS, and C. perfringens
remained significantly associated with NMO for the com-
parison of patients with rituximab-treated NMO and
rituximab-treated MS.
a
b
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Fig. 2 Differential abundance of bacterial taxa in neuromyelitis optica
(NMO) and multiple sclerosis (MS) in comparison to healthy controls
(HC). A total of 2621 organizational taxonomic units (OTUs) were
detected in at least 1 stool sample. (A) Of these, 829 OTUs were
differentially abundant between NMO and HC, whereas 277 OTUs
were differentially abundant between MS and HC (uncorrected, p <
0.05). (B) After correction for multiple comparisons (the threshold for
significance is p = 1.91 × 10-5), 42 OTUs remained differentially
abundant for the NMO vs HC comparison, whereas no taxa remained
associated with MS. Reproduced from Cree, et al., Ann Neurol 80:443-
447 (2016), with permission of John Wiley & Sons [54]
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Fig. 3 Clostridium perfringens abundance was significantly increased in
neuromyelitis optica (NMO). The abundance of gut C. perfringens was
compared between NMO, multiple sclerosis (MS), and healthy controls
(HC). Purple dots represent individual values for patients receiving
rituximab. The y-axis represents the HybScore, a measure of relative
abundance. Orange dots represent patients receiving treatment other
than rituximab, or no treatment. Reproduced from Cree, et al., Ann
Neurol 80:443-447 (2016), with permission of John Wiley & Sons [54]
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Potential Roles of Clostridium perfringens
in NMO Pathogenesis
Two NMO investigations, one that evaluated specificity of
AQP4-reactive Tcells and one that examined the microbiome,
both provided findings that could support a role for
C. perfringens in NMO. Based upon those results, we hypoth-
esized that C. perfringens may have dual functions in NMO
pathogenesis: it may 1) serve as its own proinflammatory
adjuvant, promoting Th17 polarization; and 2) expose a deter-
minant of a ClostridiumABC-TP that cross-reacts with AQP4
leading to expansion of AQP4-reactive T cells (see Fig. 4).
Such a bold hypothesis should be balanced by some skepti-
cism. Clostridium is ubiquitous, but NMO is rare. So, why
would there be an association? Several possibilities exist.
C. perfringens could act in concert with either, or both, envi-
ronmental and genetic factors that predispose to NMO.
Intrinsic molecular characteristics of Clostridia or its metabol-
ic products, independent of antigenicity, are important.
Dietary and endogenous lipid composition influences the bal-
ance between Treg and Th17 cells [62]. Specifically, short-
chain fatty acids, for example, butyrate, propionate, and ace-
tate, produced by anaerobic commensal bacteria in the colon
by metabolism of undigested complex carbohydrates, pro-
mote development of Treg [40, 41]. In contrast, long-chain
fatty acids, including lauric acid, through their influence on
the retinoid orphan receptor gamma t, the central regulator of
Th17 differentiation [63], promote expansion of Th17 cells
[62, 64]. Reconstitution of germ-free mice with Treg-
promoting Clostridia strains from clusters IV, XIVa, and
XVIII has been associated with increased levels of short-
chain fatty acids and transforming growth factor-β1 in the
cecum [50]. However, C. perfringens is a species within clus-
ter I [65]. Thus, one can speculate that dysbiosis of
C. perfringens could influence the balance favoring long-
chain fatty acids in the gut in humans, and like segmented
filamentous bacteria in mice, promote Th17 differentiation
[51]. Similarly, C. perfringens might cooperate with other
local host metabolic factors, including high dietary salt [66]
or epithelial serum amyloid A [67, 68], which can act as ad-
juvants promoting Th17 differentiation [66–68].
Examples of molecular mimicry are well recognized in
autoimmune disorders [12–14]. While our data examining T-
cell reactivity to AQP4 support molecular mimicry, it is diffi-
cult to imagine how this mechanism could apply to all patients
with NMO. First, T-cell antigen recognition is “MHC-restrict-
ed” by the capability of a peptide to bind specific (allelic)
MHC molecules. However, NMO is associated with multiple
allelic HLA-D genes. At this time, it is not clear whether each
of those allelic MHC II molecules can serve as restricting
elements for presentation of the immunodominant AQP4 de-
terminant or the C. perfringens ABC-TP mimic. Second, not
all patients with NMO are AQP4 seropositive. Currently, T-
cell reactivity to AQP4 has been examined in patients with
“classic” AQP4-seropositive NMO but not in AQP4-
seronegative patients. Thus, it is unknown whether T cells
from AQP4-seronegative patients exhibit similar reactivity to
the immunodominant AQP4 T-cell epitope or, alternatively,
whether other autoantigens serve as targets in NMO. In this
context, in 2014, several groups described patients with an
opticospinal inflammatory disease resembling NMO that
was associated with antibodies to myelin oligodendrocyte gly-
coprotein (MOG) and referred to this disorder as MOG NMO
spectrum disorder (MOG-NMOSD) [69–71]. Whether this
“non-classical NMO-like” disorder is truly NMO was first
questioned a short time later [72], and has since remained
controversial. Unlike AQP4, which is expressed abundantly
on astrocytes, MOG is an oligodendrocyte-produced myelin
Table 1 Twelve most significant organizational taxonomic units (OTUs) that differentiate neuromyelitis optica (NMO) from healthy controls (HC)*
Phylum Class Order Family Genus Species p-value
Fibrobacteres Unclassified Unclassified Unclassified Unclassified Unclassified 2.63 × 10-8
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium perfringens 5.24 × 10–8
Tenericutes Mollicutes Acholeplasmatales Acholeplasmataceae Acholeplasma Unclassified 9.21 × 10–8
Firmicutes Clostridia Clostridiales Unclassified Unclassified Unclassified 2.21 × 10–7
Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus Unclassified 2.24 × 10–7
Bacteroidetes Bacteroidia Bacteroidales Unclassified Unclassified Unclassified 2.68 × 10–7
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia producta 3.95 × 10–7
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 97otu18529 4.71 x 10-7
Firmicutes Clostridia Clostridiales Unclassified Unclassified Unclassified 6.31 × 10–7
Proteobacteria Alphaproteobacteria Unclassified Unclassified Unclassified Unclassified 6.75 × 10–7
Firmicutes Clostridia Clostridiales Lachnospiraceae Unclassified Unclassified 7.33 × 10–7
Elusimicrobia Elusimicrobia FAC88 91otu12128 94otu9638 97otu81717 7.61 × 10–7
*OTUs that significantly differed in abundance between NMO and HC after adjusting for multiple comparisons (p < 1.91 × 10–5 ), ranked in order of
decreasing statistical significance. Adapted from Cree, et al., Ann Neurol 80:443-447 (2016), with permission of John Wiley & Sons [54]
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antigen and is a candidate antigen in MS. Nevertheless, the
apparent heterogeneity in NMO or NMO-like conditions
highlights concern in identifying one pathogenic mechanism
for all similarly affected patients.
Fig. 4 Model illustrating potential roles of Clostridium perfringens in
neuromyelitis optica (NMO) pathogenesis. (Left) “Healthy microbiota”.
Commensal bacteria, including Bacteroides fragilis and certain species
within Clostridia clusters IV, XIVa, and XVIII, promote T-cell immune
regulation [47, 49, 50]. Bacteria bind to M cells, which are concentrated
in the terminal ileum and appendix in proximity to Peyer’s patches, a gut-
associated lymphoid tissue (GALT), and are highly specialized to engulf
microbial antigens and deliver them to antigen presenting cells (APCs)
[55, 56], including dendritic cells (DC) and macrophages. APCsmay also
ingest bacterial antigens directly. The APCs, including regulatory
CD103+ DC, produce anti-inflammatory cytokines (e.g., transforming
growth factor-β) that promote expansion of antigen-specific regulatory
T cells (Tregs). Those Tregs, along with T follicular helper cells (Tfh), a
specialized subset of T cells that directs B-cell maturation, class-switch
recombination, and differentiation into immunoglobulin-secreting plasma
cells [18], promote production of bacteria-specific IgA [57, 58], which is
the most abundant immunoglobulin subclass in the gastrointestinal tract.
Individual IgA molecules enter gut epithelial cells and form IgA dimers,
which are secreted (sIgA) into the intestinal lumen andmucus layer where
they bind their specific bacterial targets. Bacteria-specific sIgA are known
to alter microbiota composition and are thought to protect against
inflammation and disease [57–59]. (Right) “NMO dysbiosis”.
Overabundance of C. perfringens (CP) may elicit proinflammatory
aquaporin-4 (AQP4)-specific T-cell and B-cell responses that contribute
to development of NMO. CP binds toM cells or APC as described above.
Processing of CP by APCs exposes a determinant of the ABC-TP (p204-
217) that shares homology to AQP4 (p63-76), and when presented by
APC, leads to activation and expansion of T cells that recognize either of
these antigens (“molecular mimicry”) [31]. CP may expose products that
promote secretion of the APC-derived proinflammatory Th17-polarizing
cytokines (e.g., interleukin-6) that are increased in patients with NMO
[31, 60, 61] leading to expansion of ABC-TP/AQP4-reactive T cells.
Those Th17 cells, along with Tfh within GALT or in other secondary
lymphoid tissues, promote AQP4-specific B cells to differentiate into
plasma cells that secrete pathogenic AQP4-specific IgG1. In
conjunction with other leukocytes (e.g., neutrophils and eosinophils),
ABC-TP/AQP4-specific Th17 cells and AQP4-specific IgG target
AQP4 in the central nervous system (CNS) causing inflammation of the
optic nerves and spinal cord. Image courtesy of Xavier Studio
The Gut Microbiome in Neuromyelitis Optica 97
Ubiquitous in normal gut flora, C. perfringens is a diverse
species that is recognized as a pathogen in several conditions.
Fewer than 5% produce aC. perfringens enterotoxin, encoded
by the gene cpe located in either the bacterial chromosomal or
plasmid DNA [73]. Clostridium perfringens strains are classi-
fied into 5 subtypes (A–E) according to the particular toxin
produced [73, 74]. Type A, which can produce the α entero-
toxin, is a common cause of food poisoning and is also asso-
ciated with gas gangrene. Ayear after we proposed a potential
role for commensal C. perfringens in NMO, another group of
investigators found evidence suggesting that type B
C. perfringens might contribute to MS pathogenesis [75].
Type B C. perfringens produces an ε toxin (ETX) that has
tropism for the CNS and can cause disruption of the BBB
and injure neurons, astrocytes, and oligodendrocytes [76,
77]. Our microbiome study [54], which included patients with
NMO and MS, and other larger investigations dedicated to
MS and HC [45, 46, 78, 79], did not identify statistically
significant elevations of C. perfringens in MS gastrointestinal
microbiota. Nonetheless, it remains possible that
C. perfringens ETX participates in pathogenesis in a subset
of patients with MS. Because the C. perfringens ETX can
cause BBB damage, BBB disruption facilitates CNS entry of
AQP4-specific IgG1, and C. perfringens is overabundant in
NMO, it may be important to search for the presence and
potential contribution of pathogenic C. perfringens subtypes
in gut microbiota in NMO.
Future Challenges
Results from our analysis of fecal bacteria in NMO indi-
cated that the gastrointestinal microbiota in NMO is dis-
tinct from HC and MS, supporting the hypothesis that
there may be dysbiosis of C. perfringens [54]. However,
other candidate bacteria may participate in NMO patho-
genesis. In this respect, certain bacteria (e.g., Prevotella
copri and an unclassified species of Enterobacteriaceae)
had greater effect sizes in comparison to HC, but their
associations with NMO were less statistically significant
than C. perfringens [54]. Further, only Fibrobacteres, a
genus containing two cellulose-degrading bacterial spe-
cies found in cattle and pigs [80], was more significantly
associated with NMO than C. perfringens, and its effect
size was similar. The biological significance of these as-
sociations is unclear and deserves further investigation. It
is also important to recognize that the relative abundance
of individual bacterial species is not uniform throughout
the gastrointestinal tract. Therefore, examination of mi-
crobiota in fecal samples may not entirely reflect the rel-
ative abundance of individual species within their pre-
ferred niches.
Definitive answers regarding the role of microbiota in
NMOwill require research in both human subjects and animal
models. It is important to replicate the initial analysis of gut
microbiota with larger sample sizes. Owing to the potential
impact of immunosuppressive therapies on gut microbiota,
future studies should include larger numbers of patients with
untreatedNMO,which presents a logistic challenge as therapy
is typically initiated shortly after diagnosis. As NMO is a rare
disease, this research will likely require a coordinated effort
among many centers. Further, while similar studies may clar-
ify associations between individual bacterial populations and
NMO, they will not permit determination of causality.
Gastrointestinal dysbiosis may promote proinflammatory T-
cell polarization and, conversely, cellular and humoral immu-
nity can influence intestinal microbial community composi-
tion (see Fig. 4) [57–59]. Evidence supporting a direct role for
gut microbiota from disease-affected patients or a distinct can-
didate bacterial species, like C. perfringens, may be
established through colonization of germ-free mice with fecal
samples from patients or by monocolonization with individual
bacterial species. Recently, a clinical model of autoimmune
opticospinal inflammatory disease that is initiated by Th17
AQP4-specific T cells was established [81–84]. The develop-
ment of this new model had eluded investigators until it was
learned that AQP4-specific T cells and B cells are regulated
more stringently by mechanisms of central (thymic) and pe-
ripheral tolerance than myelin-specific T cells that cause EAE
[82–84]. By taking advantage of this model and related models
it will now be possible to examine how colonization of gut
microbiota from patients with NMO or monocolonization with
C. perfringens may influence expansion of those pathogenic
AQP4-specific T cells in vivo.
We have only scratched the surface in understanding gut
dysbiosis in NMO. Nevertheless, it is important to consider its
potential therapeutic implications. Is it possible to alter the gut
microbiota, possibly through diet or fecal microbiota trans-
plantation (FMT), in a beneficial manner in patients with
NMO? In this regard, fecal transplantation has been effective
in > 80% of patients with severe recurrent diarrhea caused by
antibiotic-resistant C. difficile colitis [85]. It is important to
recognize that manipulating factors, for example, microbial
composition, which may have participated at a certain step(s)
within the pathogenic pathway of a complex chronic inflam-
matory disease, may or may not necessarily translate thera-
peutically. However, given the severity of NMO, the potential
benefit of FMT and its low risk, testing FMT in NMO should
be given serious consideration. Based upon provocative re-
sults from studies involving patients with NMO, we have
proposed potential mechanisms to explain how dysbiosis
may participate in NMO pathogenesis. While they may be
correct, partly right, or incorrect, it is clearly important to test
these hypotheses, especially as such investigation may fill
critical gaps in our understanding of NMO pathogenesis.
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